宜宾内双也可以割双眼皮吗(宜宾割双眼皮公立医院) (今日更新中)

BEIJING, Jan. 8 (Xinhua) -- China's central authorities have highlighted travel safety as the nation on Sunday officially kicked off the world's largest holiday migration, a time in which mass numbers of passengers will be homeward bound for the traditional Chinese Spring Festival.Safe travel has emerged as a hot-button issue facing the government as passenger trips during the 40-day travel peak are expected to hit a record high of over 3 billion.Liu Tienan, vice chief of the National Development and Reform Commission, the country's top economic planner, told the press on Sunday that passenger transport during the period is not looking good as the enormous migration outweighs existing transportation capacities.?A volunteer guides passengers to their train at Chengdu Railway Station in Chengdu, capital of southwest China's Sichuan Province, Jan. 7, 2012. Starting from Jan. 8, 2012, China's transport system will undergo a 40-day travel rush, which is characterized by a hightened passenger flow around the time of the oncoming Chinese New Year.Liu warned of the likelihood of heavy snow and icy rain that could hamper travel while vowing greater efforts to avoid another travel disaster, as was seen in early 2008 when unprecedented heavy snow and freezing rain inundated the south of the country, bringing traffic to a standstill during the peak holiday season.A total of 3.16 billion passenger trips are expected during the next 40 days, up 9.1 percent from a year earlier, of which, 235 million trips will be made via the country's railways, up 6.1 percent year-on-year.Hu Yadong, vice minister of railways, said a daily average of 5.88 million people will make train trips during the period, 340,000 more than the corresponding period in 2011.At the Beijing Railway Station on Sunday, staff members checked passengers' train tickets and ID cards, as an ID-based train ticket purchasing system kicked off nationwide at the start of the new year in an effort to curb ticket scalping.

TEHRAN, Oct. 9 (Xinhua) -- Iran is going to launch domestically- built Navid satellite by Safir satellite launcher by the end of March 2012, the semi-official Mehr news agency reported on Sunday.Navid (promise) is a research satellite and is currently undergoing pre-launch tests, said the report without further details.In June, Iran put the Rasad (surveillance) satellite in the orbit to render images to the country.Iran put a satellite into orbit in 2009 and sent some small animals into space in 2010. It plans to send man into space by 2020.

BEIJING, Oct. 18 (Xinhuanet) -- NASA recently unveiled its new rocket design, named Space Launch System (SLS), according to media reports.The rocket will make its first unmanned flight in 2017, and the flight with astronauts aboard won't happen until 2021, according to NASA's plan.The new rocket was 320 feet in length (the space shuttle was 184 feet on the launch pad), 5.5 million pounds in weight, and with the capacity of holding four astronauts at the top speed of 25,000 miles per hour, Washington Post reported Tuesday.Compared with space shuttle and other predecessors, the new rocket will aim for much farther destinations into the space with its most powerful engine ever built, according to the plan."We're investing in technologies to live and work in space, and it sets the stage for visiting asteroids and Mars," the NASA administrator Charles Bolden briefed the media at a news conference in Washington.NASA expected to devote 3 billion U.S. dollars a year to the effort, or a total of about 18 billion U.S. dollars over the next six years, said William Gerstenmaier, the agency’s associate administrator for human exploration.The current financial condition of U.S. may slow down the pace of progress, which will be much slower than NASA's Apollo heyday in the 1960s.

BEIJING, Nov. 25 (Xinhua) -- The BRICS members should make joint efforts to help ease tension in the Middle East and support the region's countries in carrying out political transition and social reconstruction on their own, Chinese Foreign Ministry spokesman Liu Weimin said Friday.Liu made the remarks at a daily press briefing, after Vice Foreign Minister Zhai Jun attended a deputy foreign ministers' conference of the BRICS in the Russian capital of Moscow on Thursday.The BRICS countries' enhanced communication and coordination, joint maintenance of the basic principles of international law, and opposition to foreign armed interference in the region are in line with the common interests of Middle East countries and the international community, Liu said."China will make concerted efforts with the international society, including BRICS members, to make constructive contribution to the Middle East's peace, stability and development," Liu said.The spokesman quoted Zhai Jun as saying at the Moscow conference that the Middle East's situation has a significant impact on international politics, economy and security in addition to the impact on the political and social situations in the region.It conforms with the common interests of the region's countries and the international community for the Middle East to be politically open and inclusive, independent in foreign policy, sustainable in economic development, and peaceful and stable in security matters, Zhai was quoted as saying.Liu Weimin said a joint communique was issued at the Moscow conference. The communique called on various parties to respect the state sovereignty and territorial integrity of the Middle East countries, have extensive dialogues by peaceful means, and make active efforts to seek solutions to the crisis.The BRICS members oppose the interference in the Middle East countries' internal affairs by foreign forces, advocate the positive role of the United Nations Security Council, and urge various parties to strictly observe the authorization of the UN Security Council, according to Liu.BRICS is an acronym for Brazil, Russia, India, China and South Africa.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

来源：资阳报